Winthrop Risk, MD
Neurology · Cedar Rapids, IANPI 1104804053
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,802 of the $135,984 with a category attached, or 74.9%. AbbVie accounts for 60.5% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2022 at $32,883 and has fallen 51.6% since, to $15,925 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,065 payments — averaging $65.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82K
- Biohaven Pharmaceutical Holding Company Ltd.$17K
- Biohaven Pharmaceuticals, Inc.$13K
- Teva Pharmaceuticals USA, Inc.$8K
- Pfizer$2K
- Novartis$1K
- plus $13K from 51 others
What the payments were for
- Speaking & faculty fees$101,80275%
- Travel & lodging$3,8723%
- Food & beverage$29,61122%
- Education$7001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$69,416
- QULIPTA$30,469
- NURTEC ODT$28,389
- VRAYLAR$123
- ZEPOSIA$115
How this compares
$135,984 in reported general payments places this provider in the 95th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 131 | $166,590 |
| Emgality PenGalcanezumab-Gnlm | 178 | $142,013 |
| Kesimpta PenOfatumumab | 13 | $116,164 |
| UbrelvyUbrogepant | 71 | $108,382 |
| QuliptaAtogepant | 70 | $108,084 |
| XcopriCenobamate | 40 | $76,721 |
| BotoxOnabotulinumtoxina | 43 | $55,867 |
| Aimovig AutoinjectorErenumab-Aooe | 65 | $49,671 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 32 | $48,424 |
| VraylarCariprazine Hcl | 26 | $46,097 |
| LinzessLinaclotide | 53 | $37,593 |
| BriviactBrivaracetam | 15 | $20,953 |
| NeuproRotigotine | 16 | $18,839 |
| FycompaPerampanel | 12 | $14,429 |
| ReyvowLasmiditan Succinate | 17 | $13,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox, Vraylar, Linzess | $82,231 | $356,024263 claims |
| PfizerNurtec Odt | $1,684 | $166,590131 claims |
| SK Life Science, Inc.Xcopri | $805 | $76,72140 claims |
| UCB, Inc.Briviact, Neupro | $100 | $39,79131 claims |
| Eisai Inc.Fycompa | $397 | $14,42912 claims |
| Lilly USA, LLCReyvow | $1,131 | $13,04817 claims |
| Axsome Therapeutics, Inc.Sunosi | $1,086 | $10,68112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $69 | $10,65620 claims |
| AstraZenecaSymbicort | $34 | $2,86712 claims |
| Upsher-smith Laboratories LLCTopiramate | $124 | $1,507132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 neurology providers in Iowa.
Other neurology in Cedar Rapids
- Scott GeislerCedar Rapids$87K
- Robert StruthersCedar Rapids$2K
- Shereen ChangCedar Rapids$2K
- Thomas RogersCedar Rapids$2K
- Laurence KrainCedar Rapids$2K
- Stephanie JacksonCedar Rapids$852
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.